The chief executive of health watchdog Nice told ITV News he is "disappointed" that drug manufacturer Roche has not offered the NHS a discount on a breast cancer drug that costs around £90,000 per patient.
Kadcyla, which extends women's lives by almost six months, could be blocked from routine NHS access because it is too expensive.
"Companies can discount their prices and they frequently do. Given the list price. I would have expected the company to have at least considered (a discount)," Andrew Dillon said.
More top news
One iPhone 6 customer has learned the hard way that speed is not always of the essence when attempting to liberate his new Apple gadget.
Their relief of Scottish banks, estate agents and other businesses this morning is obvious after the country voted to stay in the UK.
The referendum story is rapidly heading south. Scottish voters were promised more power - now English and Welsh voters ask "what about us?"